Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease

Agency for Care Effectiveness (ACE)
Record ID 32018002595
Project Status: Completed
Year Published: 2022
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Singapore
MeSH Terms
  • Inflammatory Bowel Diseases
  • Ustekinumab
  • Janus Kinase Inhibitors
  • Gastrointestinal Agents
  • Antibodies, Monoclonal, Humanized
  • Colitis, Ulcerative
  • Crohn Disease
Organisation Name: Agency for Care Effectiveness (ACE)
Contact Address: Ministry of Health, College of Medicine Building, 16 College Road, Singapore 169854
Contact Name:
Contact Email:
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.